Protagonist Therapeutics Stock Today
| PTGX Stock | USD 52.65 0.40 0.75% |
PerformanceOK
| Odds Of DistressLow
|
Protagonist Therapeutics is trading at 52.65 as of the 23rd of March 2025; that is 0.75 percent decrease since the beginning of the trading day. The stock's open price was 53.05. Protagonist Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of August 2016 | Category Healthcare | Classification Health Care |
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. The company has 61.38 M outstanding shares of which 4.22 M shares are at this time shorted by private and institutional investors with about 7.43 trading days to cover. More on Protagonist Therapeutics
Moving against Protagonist Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Protagonist Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Dinesh Patel | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsProtagonist Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Protagonist Therapeutics' financial leverage. It provides some insight into what part of Protagonist Therapeutics' total assets is financed by creditors.
| |||||
Protagonist Therapeutics (PTGX) is traded on NASDAQ Exchange in USA. It is located in 7707 Gateway Boulevard, Newark, CA, United States, 94560 and employs 126 people. Protagonist Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.23 B. Protagonist Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 61.38 M outstanding shares of which 4.22 M shares are at this time shorted by private and institutional investors with about 7.43 trading days to cover.
Protagonist Therapeutics currently holds about 291.89 M in cash with 184.15 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.95.
Check Protagonist Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Protagonist Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Protagonist Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Protagonist Therapeutics. Please pay attention to any change in the institutional holdings of Protagonist Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Protagonist Ownership Details
Protagonist Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Perceptive Advisors Llc | 2024-12-31 | 1.3 M | |
| Adar1 Capital Management Llc | 2024-12-31 | 1 M | |
| Deep Track Capital, Lp | 2024-12-31 | 1000 K | |
| Wellington Management Company Llp | 2024-12-31 | 940.1 K | |
| American Century Companies Inc | 2024-12-31 | 928.3 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 758.7 K | |
| Amvescap Plc. | 2024-12-31 | 739 K | |
| Eversept Partners, Llc | 2024-12-31 | 678.8 K | |
| Northern Trust Corp | 2024-12-31 | 628.6 K | |
| Blackrock Inc | 2024-12-31 | 9.9 M | |
| Farallon Capital Management, L.l.c. | 2024-12-31 | 5.9 M |
Protagonist Therapeutics Historical Income Statement
Protagonist Stock Against Markets
Protagonist Therapeutics Corporate Management
| Newman Yeilding | Chief EVP | Profile | |
| Mohammad Masjedizadeh | Executive Officer | Profile | |
| Abha Bommireddi | Executive Management | Profile | |
| Matthew JD | Executive Counsel | Profile | |
| Matthew Gosling | Executive Counsel | Profile | |
| Richard Shames | Chief Medical Officer | Profile |
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.